High-Dose Chemotherapy Plus Peripheral Stem Cell Transplantation in Treating Patients With Hematologic Cancer

You may be eligible if

• DISEASE CHARACTERISTICS:
• Histologically diagnosed:
• * Acute myeloid leukemia in first, second, or third complete remission or first or second early relapse
• * Acute lymphoblastic leukemia in first, second, or third complete remission or first or second early relapse
• * Hodgkin's lymphoma in second or third remission or first, second, or third relapse, or refractory
• * Non-Hodgkin's lymphoma in second or third remission or first, second, or third relapse, or refractory
• * Multiple myeloma and plasma cell leukemia in second or third remission or first, second, or third relapse, or refractory
• * Myelodysplastic syndrome deemed suitable for allogeneic bone marrow transplantation
• No symptoms or signs of CNS involvement and CNS is disease free on lumbar puncture and brain CT scan
• No active meningeal cancer
• PATIENT CHARACTERISTICS:
• Age:
• 4 to 55 (4 to 60 if donor is identical twin)
• Performance status:
• ECOG 0-2
• Life expectancy:
• Not specified
• Hematopoietic:
• Not specified
• Hepatic:
• SGOT/SGPT less than 3 times normal
• Bilirubin less than 2.0 mg/dL
• Renal:
• Creatinine less than 2.1 mg/dL
• Creatinine clearance at least 60 mL/min (no greater than 1.5 times normal for children under 40 kg)
• Cardiovascular:
• No uncontrolled hypertension
• No uncontrolled congestive heart failure
• No active angina pectoris requiring nitrates
• At least 6 months since prior myocardial infarction
• No major ventricular arrhythmia
• Left ventricular ejection fraction at least 45% on MUGA
• Pulmonary:
• No severe or symptomatic restrictive or obstructive lung disease
• FEV\_1 greater than 50% of predicted
• DLCO greater than 50% of predicted
• Neurologic:
• No severe central or peripheral neurologic abnormality
• Other:
• Must have HLA-A,B,C,D/DR identical sibling age 4 to 65, in good health
• No insulin-dependent diabetes mellitus
• No major thyroid or major adrenal dysfunction
• No active infection
• No other active malignancy
• Not pregnant
• HIV negative
• HTLV-I and HTLV-II negative
• PRIOR CONCURRENT THERAPY:
• Biologic therapy:
• No excessive anthracycline exposure, unless endomyocardial biopsy shows less than grade 2 drug effect and cardiac scan shows at least 50% ejection fraction
• At least 1 year since prior autologous bone marrow or peripheral blood progenitor cell transplant or allogeneic bone marrow transplant
• Chemotherapy:
• At least 3 weeks since prior chemotherapy
• No prior excessive carmustine and bleomycin
• Endocrine therapy:
• Not specified
• Radiotherapy:
• At least 3 weeks since prior radiotherapy
• Surgery:
• Not specified
• Other:
• No concurrent nitroglycerin for angina pectoris
• No concurrent anti-arrhythmic drugs for major ventricular dysrhythmias